BSIM Therapeutics is a biotech company focuses on neurodegenerative amyloid diseases by efficient computational methodologies.
BSIM therapeutics is a spin-off company founded by Carlos J. V. Simoes, PharmD, PhD and Rui M. M. Brito, BSc, PhD, scientific work carried out at the University of Coimbra, in collaboration with the University of Leeds providing therapies through molecular modeling and cheminformatics tools.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/bsim-” connections=”true” suffix=””]
BSIM utilizes computer-based technologies to develop high-quality molecules for the treatment of challenging diseases. Companys most advanced discovery programme AMILOTERA targets transthyretin-related amyloid diseases.
In Aug 2016, BSIM Therapeutics secured 1Mn Euros grant to target its lead product to the CNS and to the eye for treatment of clinical manifestations in these organs under Neurotera project. The grant was from European Regional Development Fund.
Recover your password.
A password will be e-mailed to you.